A new paper on VC-resist glioblastoma cell state out in Nature Communications
A groundbreaking new open-access paper was published in the prestigious journal, Nature Communications, titled “VC-resist glioblastoma cell state: vessel co-option as a key driver of chemoradiation resistance.”
Glioblastoma (GBM) is a devastating brain cancer with a very poor prognosis. Only 5% of patients survive after 5 years and recurrence occurs in virtually all patients. .
This new research, led by Dr. Giorgio Seano from the Institut Curie in Paris, sheds significant light on why GBM often recurs after treatment.
The study reveals a surprising discovery: cancer cells can become more aggressive and resistant to treatment by “hiding” near blood vessels.
Dr. Seano explains, “Imagine cancer cells as astute escape artists. When we hit them with radiation or chemotherapy, they change their internal makeup and find a way to evade treatment by moving closer to blood vessels, where the therapy is less effective.”
These evading and resistant cancer cells are named VC-Resist, and they may be a major reason why GBM can return after treatment.
This breakthrough has the potential to revolutionize how we fight GBM. By understanding how cancer cells use blood vessels to their advantage, researchers may be able to develop new therapies that prevent recurrence and improve patient outcomes.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023